- Psyence Group (PSYG) has successfully exported medical-grade psilocybin mushrooms to both Canada and Portugal
- The mushrooms were exported to Psilo Scientific Ltd. in Canada and Psilo Pharma Inc. in Portugal
- Dr. Neil Maresky, CEO of Psyence Group, sat down with Sabrina Cuthbert to discuss the news
- Psyence aims to be a trusted commercial supplier of psilocybin mushrooms for the legal, global medical market and commercial medical research market
- Psyence Group Inc is a science-led psychedelic platform
- Psyence Group Inc. (PSYG) opened trading at C$0.12
Psyence Group (PSYG) has successfully exported medical-grade psilocybin mushrooms to both Canada and Portugal.
The mushrooms were exported to Psilo Scientific Ltd. in Canada and Psilo Pharma Inc. in Portugal.
Dr. Neil Maresky, CEO of Psyence Group, sat down with Sabrina Cuthbert to discuss the news.
“The export of Psyence’s psilocybin mushrooms to Psilo Pharma’s Research Partner in Portugal is our first export to Europe and our second successful export to date. We are delighted that we have concluded two important exports. We aim to be a trusted commercial supplier of psilocybin mushrooms for the legal, global medical market and commercial medical research market. Psyence’s ISO22000 certified production facility is fully operational, and we are able to ramp up production in line with demand from our customers and the global medical research market.”
Psyence Group Inc is a science-led psychedelic platform led by experts in neurology, neuroscience, and drug development. The company builds and operates federally licensed commercial psilocybin cultivation and production facilities.
Psyence Group Inc. (PSYG) opened trading at C$0.12.